PHARMA-SKAN ApS: Financial statements 2017
CVR: 16275247
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
PHARMA-SKAN ApS (CVR 16275247) has filed annual accounts for 2017. In 2017, the company reported a gross profit of DKK 14,245,664 and a net result of DKK 10,745,253 compared with DKK 9,967,894 the year before. That is an increase of 7.6% compared with the year before. Equity in the 2017 report amounted to DKK 16,033,082. The solvency ratio was 42%. The company had 11 employees in the financial year.
- Gross Profit
- DKK 14,245,664
- Profit/Loss
- DKK 10,745,253
- Equity
- DKK 16,033,082
- Total Assets
- DKK 38,214,686
- Employees
- 11
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2017 | - | 14.2 mio. | 10.7 mio. | 16 mio. | 11 |
| 2016 | - | 13.2 mio. | 10 mio. | 15.3 mio. | 11 |
| 2015 | - | 15 mio. | 11.2 mio. | 15.3 mio. | 10 |
| 2014 | - | 11.5 mio. | 8.3 mio. | 14.1 mio. | 8 |
| 2013 | - | 11.4 mio. | 8.2 mio. | 15.8 mio. | 9 |
Official annual report
Keep an eye on PHARMA-SKAN ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
PHARMA-SKAN ApS has published its annual report for 2016. Gross profit came to DKK 13,236,971, and the net result was DKK 9,967,894.
As of May 29, 2017, Susanne Rasmussen is registered as director of PHARMA-SKAN ApS.
As of May 29, 2017, Berit Pia Rasmussen has stepped down as director of PHARMA-SKAN ApS.
About PHARMA-SKAN ApS
PHARMA-SKAN ApS is a Danish company of the type Anpartsselskab based in Skanderborg, founded in 1992. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ApS KBUS 38 NR. 2587. The management consists of Line Wulff and Ib Gunnar Christensen. The board consists of Jan Dam (chair), Kent Ernst Hansen, Lars Enghave Minor and Line Wulff. The company is owned by BESULA ApS. The company has 16 employees (2018). In 2025, the company reported a gross profit of DKK 12,339,941 and a net result of DKK 7,875,190 compared with DKK 11,288,304 the year before. Equity in the 2025 report amounted to DKK 8,543,005.